ArticleClinical kidney journal2025
Correcting hyponatraemia is associated with improved survival in hyponatraemic metastatic cancer patients.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Key predictors of mortality in profound hyponatremia beyond the correction rate.Clinical kidney journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Hyponatraemia in cancer patients admitted to the hospital is associated with longer stays, higher costs and increased mortality. We examined the impact of hyponatraemia correction on survival in hospitalized patients with advanced cancer. Methods: We reviewed records of patients with solid tumours who were hospitalized between January 2018 and December 2022 with serum sodium ≤125 mEq/l at admission. Cox regression analysis examined associations of demographic and clinical characteristics, including sodium levels at admission and discharge, with overall survival. Results: Among 1100 patients, median sodium levels were 122 mEq/l at admission and 132 mEq/l at discharge. A total of 165 patients (15%) died during hospitalization and 414 of 688 discharged home (60.2%) died within 5 years. Multivariable analysis showed that among patients discharged alive, a decrease in sodium from admission to discharge ( Conclusions: Correcting hyponatraemia in hospitalized patients with metastatic cancer increases overall survival, but metastatic cancer in itself is also associated with poor survival. This highlights the importance of early palliative care involvement in patients with advanced cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.